Introduction: Parents’ behavior and practices affect many aspects of family life, including health, and many studies have proven that children's bad habits are associated with parents’ behavior and practices. Objectives: This study aimed to identify parents’ negative behaviors that might affect their families’ health and social development. Methodology: A descriptive cross-sectional study was conducted to examine the influence of parents’ behavior and practices on their family health, in which 192 respondents participated. Results: The results clarified the influence of parents on family health in several aspects. On the behavioral side, approximately 90% of the participants agreed that the behavior of parents may affect the behavior of their families, and the social and educational side results clarified the relationship between parents' illiteracy and support for the cognitive and social health of the family. Discussion: This study clarified that there is a significant relationship between illiterate parents and their ability to support their families, illustrating that the majority of participants thought that the development of the cognitive and social health of families depends on the presence of supportive parents, which has many implications for family social and psychological health. Conclusion: Parental behaviors and practices have a strong effect on their family’s health, which affects the development of the families’ cognitive and social health. Recommendation: The study recommends the need for supportive, friendly hospitals for family social health and the provision of specialized programs that support the family’s social and psychological health.

Background: World Health Organization (WHO) estimates that there were 558000 new cases with resistance to Rifampicin, of which 82% had multidrug-resistant tuberculosis (MDR-TB). Objectives: We aimed to identify the prevalence of MDR-TB in River Nile state, Sudan, and the risk factors contributing to its occurrence. Methods: This was a descriptive cross-sectional hospital-based study involved 200 specimens taken from patients suspected of having MDR-TB tested using an automated GeneXpert assay. Results: Results of GeneXpert assay showed that the presence of Mycobacterium tuberculosis in 81 (40.5%), and out of 81 positive test results there were 13 (16%) had MDR-TB. Additionally, 7 cases of MDR-TB were previously treated which represented about (53%) of MDR patients, the remaining 6 MDR-TB patients were new cases and represented (47%) of MDR-TB patients. Moreover, there were 4 MDR-TB patients who had a history of contact with MDR-TB patients. Conclusion: Prevalence of MDR-TB in River Nile State, Sudan was 16%, which is greater than WHO estimation for Sudan (10.1%). The results revealed that the main risk factor to develop MDR-TB was a history of contact with MDR-TB, so adherence to treatment and social awareness about the spread of MDR-TB are crucial preventive measures.

Alzheimer's disease is a multifactorial neurodegenerative disorder, with Acetylcholinesterase, Butyrylcholinesterase, Beta secretase, Glycogen Synthase Kinase beta and Monoamine oxidase B playing central role in it's pathogenesis. Therefore, this research aims to discover potential curative multitarget drugs derived from African natural products capable of addressing the multifactorial characteristics of the disease. In silico approaches were used to filter a 880 african natural compounds library based on selected pharmacokinetic properties. Molecular docking against the five aforementioned proteins, followed by Molecular Mechanics with Generalised Born and Surface Area Solvation scoring for the top compounds were used to assess binding. Density Functional Theory studies were used to assess electronic transitions. Pharmacokinetic filters resulted in 200 compounds, of which only five were selected after molecular docking. Density Functional Theory and Molecular Mechanics with Generalised Born and Surface Area Solvation scoring resulted in 3 potential multitarget compounds. Compound 157 (ZINC000095485950) showed triple-target inhibitory activity against Butyrylcholinesterase, Glycogen Synthase Kinase beta and Beta-secretase, while compounds 159 (ZINC000095485952) and 696 (ZINC000039144622) showed dual-target inhibitory activity against Butyrylcholinesterase and Glycogen Synthase Kinase beta. Molecular dynamics simulation and further experimental assessments are suggested.